These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

535 related articles for article (PubMed ID: 22759639)

  • 21. A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient?
    Hatzimouratidis K; Hatzichristou DG
    Drugs; 2005; 65(12):1621-50. PubMed ID: 16060698
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Medication utilization behavior in patients receiving phosphodiesterase type 5 inhibitors for erectile dysfunction.
    Mulhall JP; McLaughlin TP; Harnett JP; Scott B; Burhani S; Russell D
    J Sex Med; 2005 Nov; 2(6):848-55. PubMed ID: 16422809
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence and medical management of erectile dysfunction in Asia.
    Park K; Hwang EC; Kim SO
    Asian J Androl; 2011 Jul; 13(4):543-9. PubMed ID: 21460862
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The selectivity and potency of the new PDE5 inhibitor TPN729MA.
    Wang Z; Zhu D; Yang X; Li J; Jiang X; Tian G; Terrett NK; Jin J; Wu H; He Q; Yang B; Shen J
    J Sex Med; 2013 Nov; 10(11):2790-7. PubMed ID: 23937247
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nebivolol potentiates the efficacy of PDE5 inhibitors to relax corpus cavernosum and penile arteries from diabetic patients by enhancing the NO/cGMP pathway.
    Martínez-Salamanca JI; La Fuente JM; Cardoso J; Fernández A; Cuevas P; Wright HM; Angulo J
    J Sex Med; 2014 May; 11(5):1182-92. PubMed ID: 24877179
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of avanafil for treating erectile dysfunction: results of a multicentre, randomized, double-blind, placebo-controlled trial.
    Zhao C; Kim SW; Yang DY; Kim JJ; Park NC; Lee SW; Paick JS; Ahn TY; Moon KH; Chung WS; Min KS; Suh JK; Hyun JS; Park K; Park JK
    BJU Int; 2012 Dec; 110(11):1801-6. PubMed ID: 22448738
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Avanafil for erectile dysfunction.
    Kyle JA; Brown DA; Hill JK
    Ann Pharmacother; 2013 Oct; 47(10):1312-20. PubMed ID: 24259695
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of the phosphodiesterase 5 inhibitors sildenafil, tadalafil and vardenafil on rat anococcygeus muscle: functional and biochemical aspects.
    Toque HA; Priviero FB; Zemse SM; Antunes E; Teixeira CE; Webb RC
    Clin Exp Pharmacol Physiol; 2009 Apr; 36(4):358-66. PubMed ID: 18986324
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of phosphodiesterase type 5 (PDE5) inhibitors in treating erectile dysfunction after bilateral nerve-sparing radical prostatectomy.
    Cui Y; Liu X; Shi L; Gao Z
    Andrologia; 2016 Feb; 48(1):20-8. PubMed ID: 25684196
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The ENDOTRIAL study: a spontaneous, open-label, randomized, multicenter, crossover study on the efficacy of sildenafil, tadalafil, and vardenafil in the treatment of erectile dysfunction.
    Jannini EA; Isidori AM; Gravina GL; Aversa A; Balercia G; Bocchio M; Boscaro M; Carani C; Corona G; Fabbri A; Foresta C; Forti G; Francavilla S; Granata AR; Maggi M; Mansani R; Palego P; Spera G; Vetri M; Lenzi A;
    J Sex Med; 2009 Sep; 6(9):2547-60. PubMed ID: 19570039
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The molecular basis for the selectivity of tadalafil toward phosphodiesterase 5 and 6: a modeling study.
    Huang YY; Li Z; Cai YH; Feng LJ; Wu Y; Li X; Luo HB
    J Chem Inf Model; 2013 Nov; 53(11):3044-53. PubMed ID: 24180640
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Are phosphodiesterase type 5 inhibitors associated with vision-threatening adverse events? A critical analysis and review of the literature.
    Azzouni F; Abu samra K
    J Sex Med; 2011 Oct; 8(10):2894-903. PubMed ID: 21771280
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction.
    Corbin JD; Francis SH; Webb DJ
    Urology; 2002 Sep; 60(2 Suppl 2):4-11. PubMed ID: 12414329
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical update on phosphodiesterase type-5 inhibitors for erectile dysfunction.
    Briganti A; Salonia A; Deho' F; Zanni G; Barbieri L; Rigatti P; Montorsi F
    World J Urol; 2005 Dec; 23(6):374-84. PubMed ID: 16273417
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Data on the utilization of treatment modalities for ED in Taiwan in the era of PDE5 inhibitors.
    Tsai WK; Jiann BP
    Int J Impot Res; 2014; 26(4):141-5. PubMed ID: 24451166
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Avanafil, a new rapid-onset phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction.
    Limin M; Johnsen N; Hellstrom WJ
    Expert Opin Investig Drugs; 2010 Nov; 19(11):1427-37. PubMed ID: 20939743
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapy of ED: PDE-5 Inhibitors.
    Shabsigh R
    Endocrine; 2004; 23(2-3):135-41. PubMed ID: 15146092
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of clinical trials with sildenafil, vardenafil and tadalafil in erectile dysfunction.
    Doggrell SA
    Expert Opin Pharmacother; 2005 Jan; 6(1):75-84. PubMed ID: 15709885
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized, double-blind, placebo-controlled, parallel study to assess the efficacy and safety of once-a-day tadalafil in men with erectile dysfunction who are naïve to PDE5 inhibitors.
    Montorsi F; Aversa A; Moncada I; Perimenis P; Porst H; Barker C; Shane MA; Sorsaburu S
    J Sex Med; 2011 Sep; 8(9):2617-24. PubMed ID: 21707928
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Useful Implications of Low-dose Long-term Use of PDE-5 Inhibitors.
    Mostafa T
    Sex Med Rev; 2016 Jul; 4(3):270-284. PubMed ID: 27871960
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.